The Motley Fool Discussion Boards

Previous Page

Stocks F / FoxHollow Technologies


Subject:  My 2 cents worth Date:  4/18/2007  1:03 PM
Author:  dtrapp Number:  22 of 24

Hey folks,

Everybody's MBA's not withstanding, just a word from the clinical arena. I do not own Fox Hollow, but am intimately familiar with the Silverhawk since I work in Vascular sales. There are several issues with Silverhawk that I will list. First and foremost, long term patency is poor with this product. A recent study cited 80% patency out to 6 months, but a dismal 20% after 6 months. This means treated vessels are not staying open and require additional therapy.
The second issue is cost. Hospital administrators hate this product precisely because it is expensive and does not deliver. At this time there is no cure for intimal hyperplasia or PAD, until that occurs I believe this stock is going to be a disappointment .
Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us